Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, researchers describe a 13-year-old phenotypic female with 46,XY karyotype, previously misdiagnosed with androgen insensitivity syndrome, who was later identified to have 17-beta-hydroxysteroid dehydrogenase type 3 deficiency, underscoring the importance of genetic and hormonal tests for accurate diagnosis of sex development disorders.

This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.

This study found that sebaceous glands predominantly exhibit oxidative activity of the type 2 17β-hydroxysteroid dehydrogenase isozyme, which is not inhibited by 13-cis retinoic acid.

This article discusses the functions of the enzyme 17beta-HSD10, including its role in steroid metabolism and potential links to Alzheimer's disease, but reports no new experimental findings.

This study reports the first case of ovarian mature cystic teratoma linked to clinical virilization due to ectopic testosterone production, possibly from overexpression of the enzyme HSD17B5.

This study observes the expression of mRNA for androgen receptor, 5α‐reductase, and 17β‐hydroxysteroid dehydrogenase in human dermal papilla cells.

In this study, researchers identified and examined males with 17 beta-HSD3 deficiency in a highly inbred Arab population, noting genetic findings and the progression of male characteristics despite being raised as females initially.

Masculinization in affected individuals occurs gradually after puberty due to hormone changes.

In this study, researchers developed a novel platform for discovering potential hair loss inhibitors by investigating the testosterone/dihydrotestosterone biosynthetic pathway and its regulation through biochemical mechanisms involving 17β-HSD and 3β-HSD, combined with medicinal plant extracts.

This study identified procyanidin B2 and leucopelargonidin from Saraca asoca as potential inhibitors in PCOS by showing high binding energy scores against key enzymes involved in estrogen and testosterone biosynthesis.

This study found that androgen metabolism within hair follicles varies significantly between compartments, with dermal papillae showing high 5α-reductase activity, suggesting a key role in androgen-driven hair growth responses.

This research suggests that fluoxymesterone, an anabolic steroid, may inhibit a key enzyme, potentially contributing to cardiovascular issues by affecting cortisol's activation of mineralocorticoid receptors.

This study suggests that idiopathic hirsutism may involve higher local androgen synthesis despite normal serum androgen levels, challenging its categorization as idiopathic.

This study reported that while finasteride and progesterone significantly inhibited dihydrotestosterone synthesis in dermal papillae, estrogens were less effective.

This article reviews the genetic mutations causing male pseudohermaphroditism from 17 beta-HSD-3 and 5 alpha-RD-2 deficiencies and reports no new clinical findings.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study observed that mice lacking epidermal HSD11b1 had increased non-histaminergic itch and changes in skin nerve fibers, potentially linked to higher TSLP expression.

In this study, researchers observed that testicular 17β-hydroxysteroid dehydrogenase deficiency in an inbred Arab population in Israel leads to genital ambiguity at birth and progressive virilization after puberty.

This study found that SZ95 sebocytes and HaCaT keratinocytes exhibit distinct enzyme expressions and activities, implicating their different roles in androgen metabolism and homeostasis in vitro.

This study found that glioblastoma cells express key enzymes involved in androgen synthesis, suggesting these enzymes might be potential targets for new therapeutic strategies.

This study found that untreated hirsute patients have lower expression of type 2 17β-HSD mRNA in scalp hairs, indicating potential disturbances in androgen metabolism, compared to treated hirsute patients.

This study found that dutasteride completely suppressed the formation of 5alpha-dihydro metabolites in cultured human skin cells, suggesting its potential use in acne and androgenetic alopecia.

This study found that sulforaphane treatment enhanced hair regeneration in ob/ob mice by increasing DHT-degrading enzyme levels and lowering plasma testosterone and DHT.

This review discusses phenotypic differences in testosterone production between mice and humans with HSD17B3 deficiency and reports no new findings; the authors highlight potential pathways and enzymes involved in testosterone synthesis.

This study discusses the potential of targeting 11β-HSD1 for treating metabolic syndrome and highlights emerging promising data from human trials on selective 11β-HSD1 inhibitors.

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

This review discusses the potential of targeting glucocorticoid action as a treatment strategy for obesity and type-2 diabetes, highlighting promising animal study results but reports no new clinical findings.

The authors concluded that increased expression of the HSD11B1 gene in adipose tissue correlates with obesity markers and predicts insulin resistance, but this association is independent of polycystic ovary syndrome when adiposity is controlled for.

This study found that 11α-hydroxyprogesterone is a potent inhibitor of 11βHSD2 in vitro and may serve as a precursor to unique C11α-hydroxy steroids in prostate cancer tissue.

This study found that inhibiting 11β-HSD1 can partially reverse the negative impact of glucocorticoids on dermal papilla cells in human scalps, suggesting potential for treating stress-related hair loss.